Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
一项评估 TLR9 激动剂 cavrotolimod 与抗 PD-1 抗体联合治疗晚期实体瘤患者的安全性、有效性和免疫效应的 1b/2 期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-011651
Milhem, Mohammed M; Wise-Draper, Trisha M; Chandra, Sunandana; Hanna, Glenn J; Laux, Douglas E; Medina, Theresa M; Ansstas, George; Daud, Adil; Kelly, Ciara M; O'Day, Steven J; Perez, Cesar A; Wong, Michael K; Friedlander, Philip A; Kristedja, Timothy S; Burgess, Melissa A; Cowey, C Lance; Hanks, Brent A; Weight, Ryan M; Daniel, Weston L; Feltner, Douglas E; Mix, Scott; Sindelar, Laurel; Bexon, Alice S; Bexon, Martin F; Michel, Robert E; Bhatia, Shailender
